

Alfasigma – Withdrawal of Zelnorm[®] (tegaserod)

- On June 28, 2022, [Alfasigma announced](#) that [Zelnorm \(tegaserod\)](#) will be withdrawn from the market. The discontinuation is a business decision and is not due to safety, quality or efficacy issues, or any recall imposed on the product.
- Zelnorm is indicated for the treatment of adult women less than 65 years of age with irritable bowel syndrome with constipation (IBS-C).

Product Description	NDC#
Zelnorm (tegaserod) 6 mg tablets	00525-0971-60

- Other medications indicated for the treatment of IBS-C include brand and generic [Amitiza[®] \(lubiprostone\)](#), brand [Linzess[®] \(linaclotide\)](#), and brand [Trulance[®] \(plecanatide\)](#).
- Patients should contact their physician or health care provider if they have any questions regarding their Zelnorm therapy.
 - 0.019). Over the course of the study, the event rate (percentage of patients per year) was 33.6% with Verquvo vs. 37.8% with placebo.